Is it a primary or review article Potent and Targeted Activa

Potent and Targeted Activation off Latent HIV-1 Using the CRISPR/dCas9 Activator Complex Sheena M Saayman^1, 2, Daniel C Lazar^1, Tristan A Scott^2, Jonathan R Mart^1, Mayumi Takahashi^3, John C Burnett^3, Vicente Planelles^4, Kevin V Morris^1, 5 and Marc S Weinberg^1, 2, 6^1 Deportment of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA, ^2 HIV Pathogenesis Research Unit, Deportment of Molecular Medicine and Hematology, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa;^3 Division of Molecular Biology, Beckman Research Institute at the City of Hope, Duarte, California, USA;^4 Division of Microbiology and Immunology, Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA;^5 School of Biotechnology and Biomedical Sciences, University of New Wales, Kensington, New South Wales, Australia;^6 Wits/SA MRC Antiviral Gene Therapy Research Unit, Department of Molecular Medicine and Hematology, University of the Witwatersrand, Johannesburg, South Africa

Solution

This is a primary article available in the open access journal\' Molecular Therapy\' with the following citation:

Saayman, S. M., Lazar, D. C., Scott, T. A., Hart, J. R., Takahashi, M., Burnett, J. C., … Weinberg, M. S. (2016). Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex. Molecular Therapy, 24(3), 488–498. http://doi.org/10.1038/mt.2015.202

               Combined antiretroviral therapies (cARTs), though effective in reducing the morbidity, mortality, and transmission of HIV-related illness; is least effective in eradicating latent HIV reservoirs. This leads to persistent infection even under lifelong treatment. The therapeutic attempts to eliminate such latently infected cells have been unsuccessful. In the present work, the authors have engineered a RNA-guided CRISPR-Cas9 system (involving single guide RNAs (sgRNAs) with a nuclease-deficient Cas9 mutant (dCas9) combined to the VP64 transactivation domain (dCas9-VP64)) which enhanced the efficiency and specificity in a targeted latency reactivation strategy which can be a promising approach to the “functional cure” of HIV/AIDS.